GlassScriptPhysician profile
Dan M Sodano
NPI 1063606101
$14,598.24
in general payments reported to CMS, 2019-2025
32 companies · $3,310 in 2025
The $3,310 reported for 2025 was more than what 89% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,327 · 2020: $2,894 · 2021: $1,412 · 2022: $734 · 2023: $1,274 · 2024: $1,647 · 2025: $3,310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,097 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,096.66 |
| Education | $134.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $1,554.07 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $1,179.22 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $1,137.09 | 2019-2025 | Farxiga |
| Abbott Laboratories | $1,019.05 | 2019-2022 | |
| Pfizer INC. | $955.31 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $776.84 | 2019-2025 | Lifevest |
| Amgen INC. | $774.96 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $766.22 | 2019-2025 | |
| Esperion Therapeutics, INC. | $651.30 | 2020-2025 | Nexletol, Nexlizet |
| E.R. Squibb & Sons, L.L.C. | $640.52 | 2019-2025 | Camzyos, Eliquis |
| Actelion Pharmaceuticals US, INC. | $532.90 | 2023-2025 | Uptravi, Opsumit |
| Lexicon Pharmaceuticals, INC. | $521.81 | 2023-2024 | Inpefa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $501.05 | 2019-2025 | Jardiance |
| Boston Scientific Corporation | $493.01 | 2019-2025 | Watchman Access System |
| Nuwellis, INC. | $465.74 | 2020-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $449.62 | 2023-2025 | |
| Cvrx, INC. | $443.68 | 2021-2024 | Barostim Neo System |
| Scpharmaceuticals INC. | $290.84 | 2025 | |
| Angiodynamics, INC. | $261.31 | 2019-2021 | |
| Novo Nordisk INC | $232.59 | 2021-2025 | Wegovy, Ozempic |
| Irhythm Technologies, INC. | $230.68 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Sanofi-Aventis U.S. LLC | $130.89 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $128.66 | 2019-2024 | Evkeeza |
| Allergan, INC. | $124.55 | 2019 | |
| Alnylam Pharmaceuticals INC. | $117.62 | 2024-2025 | Onpattro |
| Kowa Pharmaceuticals America, INC. | $81.10 | 2019-2023 | Livalo |
| Bridgebio Pharma, INC. | $27.70 | 2025 | Attruby |
| Penumbra, INC. | $26.32 | 2023 | Indigo System |
| Merck Sharp & Dohme LLC | $25.98 | 2021 | |
| Philips North America LLC | $20.05 | 2023 | |
| Kiniksa Pharmaceuticals, LTD. | $18.84 | 2023 | Arcalyst |
| Glaxosmithkline, LLC. | $18.72 | 2025 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Sodano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.